DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward. It’s been a volatile couple of years for the United States. President Trump’s second term has brought with it the kinds of government […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!